Stay updated with breaking news from Although Satellos. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Satellos expects to begin first-in-human clinical trials mid-year for SAT-3247, an oral small molecule drug candidate in development as a novel regenerative medicine approach to treating DMD ...
Satellos Bioscience Inc. , a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that it has been...
Satellos Bioscience Inc. , a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced a late-breaking...
Data support potential for SAT-3247 in multiple degenerative muscle diseases On track to initiate first-in-human clinical trial mid-2024 for Duchenne muscular dystrophy ...
Satellos Bioscience Inc. , a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, is pleased to announce that it...